Regeneron's DB-OTO Gene Therapy Shows Promise in Treating Otoferlin Hearing Loss

Regeneron's DB-OTO Gene Therapy Shows Promise in Treating Otoferlin Hearing Loss

Axel Koenig
1 min read

Regeneron's Breakthrough Gene Therapy Restores Hearing in Children with Otoferlin Hearing Loss

The preliminary data from Regeneron Pharmaceuticals’ gene therapy, DB-OTO, has shown remarkable success in treating otoferlin hearing loss, with an 11-month-old child's hearing completely restored and a four-year-old showing significant improvement. Presented at the 2024 ASGCT annual conference, the Phase I/II trial demonstrated the therapy's safety and effectiveness. This breakthrough could potentially reshape the landscape of audiology and genetic medicine, while intensifying the competition among companies involved in gene therapy for otoferlin hearing loss.

Key Takeaways

  • Regeneron's DB-OTO gene therapy restores hearing in an 11-month-old and improves hearing in a four-year-old with otoferlin hearing loss.
  • The data is from an open-label Phase I/II CHORD trial presented at the 2024 ASGCT annual conference.
  • DB-OTO is an adeno-associated virus gene therapy designed to restore hearing in patients with congenital otoferlin hearing loss.
  • Other companies like Sensorion and Akouos are also developing gene therapies for otoferlin hearing loss.


Regeneron's success with DB-OTO could potentially lead to collaborations, mergers, or acquisitions in the industry and impact competitors like Sensorion and Akouos. In the short term, Regeneron's reputation and stock value could receive a boost, increasing interest from both patients and investors in gene therapies. In the long term, successful treatments may become a standard for otoferlin hearing loss, bringing hope to thousands of patients.

Did You Know?

  • Gene therapy for otoferlin hearing loss involves introducing genetic material to treat the condition, while Phase I/II clinical trials evaluate safety and efficacy. DB-OTO is an adeno-associated virus gene therapy used to deliver genetic material into cells, targeting specific cell types with low risk of immune response.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings